Departed
Joseph M. Busky
Chief Financial Officer
QDEL ·
QuidelOrtho Corp
Mr. Young will succeed Joseph M. Busky, who previously announced his plans to retire
Ready 8-Ks
50
Latest filing
June 23, 2026, 4:04 PM ET
Top materiality
0.85
Event mix
earnings ×23 · leadership ×15 · other_material ×6
Sentiment
11 pos · 8 neg · 31 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for QDEL
Highest-materiality recent filing
QuidelOrtho Q1 revenue $711M, GAAP loss $25.50/share; suspends 2024 guidance after new CEO
- Total revenue $711M, down 16% YoY; ex-COVID revenue grew 5% as reported (6% constant currency).
- GAAP diluted loss per share $25.50 from $1.74B goodwill impairment; adjusted EPS $0.44 vs $1.80.
-
QuidelOrtho appoints Micah Young as CFO effective July 6, 2026
Micah Young appointed CFO, effective July 6, 2026; succeeds Joseph Busky who is retiring.
-
QuidelOrtho stockholders elect all 10 director nominees at 2026 annual meeting
All 10 director nominees elected; votes for ranged from 56.0M to 56.8M.
-
QuidelOrtho Q1 net loss $92M; revenue $620M; cuts full-year guidance
GAAP net loss $92M ($1.35 diluted loss per share); adjusted diluted EPS loss $0.04; revenue $620M.
-
QuidelOrtho prelim Q1 rev $615-620M; weaker respiratory season, China headwinds
Prelim Q1 2026 revenue of $615-$620M; U.S. flu-like illness visits down ~30% YoY.
-
QuidelOrtho appoints Nate Sisitsky as Chief Legal Officer; Michelle Hodges retires
Michelle Hodges retires as Chief Legal Officer and Corporate Secretary effective March 23, 2026; will serve as special advisor for up to 24 months.
-
CFO Joseph M. Busky to retire effective June 30, 2026
Joseph M. Busky notified QuidelOrtho of his retirement on February 9, 2026.
-
QuidelOrtho reports FY25 revenue $2.73B, adjusted EBITDA $597M; guides FY26 revenue $2.7-2.9B
FY25 total revenue $2.73B in line with guidance; Labs revenue +6% as reported, non-respiratory +5% ex Donor Screening.
-
Director Matthew W. Strobeck to not stand for re-election; Board will reduce to 10
Matthew W. Strobeck notified Board on Jan 30, 2026 of decision not to stand for re-election at 2026 annual meeting.
-
QuidelOrtho Q3: revenue $700M, adj. EBITDA margin 25%, core growth 5% YoY
Total revenue $700M; core revenue (ex-COVID/Donor Screening) grew 5% as reported.
-
QuidelOrtho Q3 revenue $700M (-4% YoY); GAAP loss $10.78/sh on $701M impairment; Adj EPS $0.80
Total revenue $700M, down 4% YoY; non-respiratory revenue up 5% as reported, 6% constant currency ex-Donor Screening.
-
QuidelOrtho refinances with $1.15B Term Loan A, $1.45B Term Loan B, $700M revolver
New credit facility includes $1.15B 5-yr Term Loan A, $1.45B 7-yr Term Loan B, $700M revolver, and $100M delayed draw Term Loan A (undrawn).
-
QuidelOrtho reports Q2 2025 adjusted EPS of $0.12 vs loss of ($0.07); reaffirms FY guidance
Q2 revenue $614M (-3.6% YoY); Labs revenue +4% as reported, but respiratory revenue fell 20% to $47M on lower COVID-19 sales.
-
QuidelOrtho stockholders approve 6.2M share increase for equity plan, reelect 11 directors
Stockholders approved Second A&R 2018 Equity Incentive Plan, increasing authorized shares by 6.2M and extending term to May 20, 2035.
-
QuidelOrtho Q1 revenue $693M, +5% ex-COVID/Donor; adjusted EPS $0.74 vs $0.44 YoY
Total revenue $693M, -3% reported due to lower COVID/Donor; ex-COVID/Donor +5% as reported and +6% constant currency.
-
QuidelOrtho appoints KPMG as auditor, dismisses EY; material weaknesses disclosed
Audit Committee selected KPMG as independent auditor for FY 2025, dismissing EY effective Feb 28, 2025, after competitive process.
-
Q4 GAAP diluted loss per share $2.28 vs EPS $0.10 prior year; adjusted EPS $0.63 vs $1.17.
-
QuidelOrtho expects Q4 2024 revenue of $702-707M, above guidance midpoint
Preliminary total revenue $702-707M, in line with prior guidance; non-respiratory $561-563M, respiratory $141-143M.
-
QuidelOrtho appoints John Chiminski and Scott Huennekens as independent directors
Appointments effective December 6, 2024; both qualify as independent under Nasdaq rules.
-
Carlyle sells 8.26M QuidelOrtho shares at $35.31; two Carlyle directors resign
Carlyle Partners VI sells 8,260,183 QDEL shares at $35.31/share; company receives no proceeds.
-
QuidelOrtho appoints Philip McLellan as COO, approves salary increase to $515K
Philip McLellan appointed Chief Operations Officer effective November 15, 2024.
-
QuidelOrtho expands CFO Busky's role to include IT oversight; salary raised to $680,000
CFO Joseph Busky assumes additional oversight of Information Technology function effective Nov 18, 2024.
-
QuidelOrtho terminates EVP CCO and EVP COO; appoints Philip McLellan as COO
Terminated Michael S. Iskra (EVP & CCO) and Robert J. Bujarski (EVP & COO), effective Nov 15, 2024.
-
QuidelOrtho Q3 GAAP net loss $20M ($0.30 EPS); revenue $727M; reinstates 2024 guidance
Revenue $727M vs $744M YoY; Labs revenue grew 4% as reported (5% constant currency).
-
QuidelOrtho Q2 2024: revenue $637M, GAAP diluted loss ($2.20)/share
Total revenue $637M, down 4% YoY; lower COVID-19 revenue was primary driver.
-
QuidelOrtho stockholders elect all 10 director nominees, approve say-on-pay, ratify EY as auditor
Ten directors elected with 97.5% to 90.9% of votes cast; highest support for Evelyn Dilsaver (95.6%), lowest for Kenneth Widder (90.9%).
-
QuidelOrtho Q1 revenue $711M, GAAP loss $25.50/share; suspends 2024 guidance after new CEO
Total revenue $711M, down 16% YoY; ex-COVID revenue grew 5% as reported (6% constant currency).
-
QuidelOrtho appoints Brian J. Blaser as CEO effective May 6, 2024
Blaser, ex-Abbott EVP Diagnostic Products, replaces interim CEO Michael Iskra and interim President Robert Bujarski.
-
QuidelOrtho amends credit agreement; leverage ratio covenant adjusted through 2025
Amendment temporarily raises max leverage to 4.25x for Q3/Q4 2024, then to 4.00x, stepping to 3.75x after June 2025.
-
QuidelOrtho sets retention comp for interim CEO, president, and CFO
Michael Iskra (Interim CEO) gets 125% base salary target bonus, cash award of 100% base salary, and $1M equity award.
-
QuidelOrtho terminates CEO Bryant, appoints Iskra as interim CEO
Douglas Bryant terminated as President and CEO effective Feb 21, 2024; he also resigns from the Board.
-
QuidelOrtho widens FY2024 adjusted diluted EPS range to $1.88-$3.60; midpoint unchanged
Corrected FY2024 adj. diluted EPS guidance: $1.88-$3.60 (midpoint $2.74 unchanged); previously narrower range.
-
QuidelOrtho Q4 revenue $743M (-14% YoY); GAAP EPS $0.10, adj. EPS $1.17; FY24 guidance issued
Q4 revenue $743M vs $867M YoY; non-respiratory +9%, respiratory -49%.
-
Stephen H. Wise resigned from board effective Nov 28, 2023, due to other professional commitments; no dispute.
-
QuidelOrtho Q3 revenue $744M, GAAP loss $0.19/sh, adj EPS $0.90; maintains FY guidance
Total revenue $744.0M, down from $783.8M YoY; respiratory revenue declined 21% as anticipated.
-
QuidelOrtho preliminary Q3 revenue $738-744M; beats on early respiratory demand
Total revenue $738-744M vs prior expectations; non-respiratory $557-560M, respiratory $181-184M.
-
Director Christopher M. Smith resigns from QuidelOrtho board effective Aug 31, 2023
Christopher M. Smith resigned from the Board effective August 31, 2023, citing other professional commitments.
-
QuidelOrtho Q2 revenue $665M, GAAP loss $(0.80)/share, adj. EPS $0.26; respiratory revenue down 74%
Revenue $665.1M (+8% reported) but down 26% on supplemental combined basis vs Q2 2022.
-
QuidelOrtho shareholders elect 12 directors, approve say-on-pay, ratify EY
All 12 director nominees elected; largest withhold was 7.3M votes for Kenneth J. Widder, M.D.
-
Q1 revenue $846.1M, down 16%; GAAP EPS $0.73, adjusted EPS $1.80
Total revenue $846.1M, down 16% YoY; non-respiratory up 5% on supplemental combined basis.
-
QuidelOrtho pre-announces Q1 revenue $840-850M; non-respiratory grows 5-7%
Total preliminary Q1 revenue $840-850M; respiratory $262-267M including COVID-19 $212-217M.
-
Werner Kroll (SVP R&D) receives $1M/year equity grants (options/RSUs) for 2023, 2024, 2025 with performance- and time-based vesting.
-
Q4 GAAP EPS $0.45 vs $6.85 prior year; supplemental adjusted EPS $1.76, down 66% YoY.
-
QuidelOrtho Q4 2022 preliminary revenue $853-868M; non-COVID rev up 18% proforma constant currency
Preliminary Q4 total revenue $853M-$868M; COVID $124M-$134M; non-COVID $729M-$734M.
-
Kenneth Buechler, Lead Independent Director, appointed non-executive Chairman effective Dec 11, 2022.
-
QuidelOrtho sets deadlines for 2023 annual meeting proposals and director nominations
Rule 14a-8 stockholder proposals must be received by Dec. 12, 2022.
-
Revenue $783.8M, +54% reported; supplemental combined revenue -21.8% constant currency; ex-COVID +3.0% (underlying +6.0%).
-
QuidelOrtho reports preliminary Q3 2022 revenue $782-785M; COVID revenue ~$171M
Total revenue expected $782M-$785M; non-COVID product revenue $611M-$614M.
-
QuidelOrtho authorizes $300M share repurchase over two years; cites confidence in cash generation
Board authorized repurchase of up to $300M of common stock through August 17, 2024.
-
QuidelOrtho reports pro forma combined revenue of $2.4B and net income of $489.9M for H1 2022
Pro forma combined revenue for six months ended July 3, 2022: $2.4B; net income $489.9M; diluted EPS $7.22.
-
QuidelOrtho Q2 supplemental combined revenue $898.5M, adj EPS $2.12, up 123% YoY
GAAP revenue $613.4M (+247% as reported) from business combination with Ortho closed May 27, 2022.
Executive changes
Appointed
Micah Young
Chief Financial Officer
QDEL ·
QuidelOrtho Corp
The Board of Directors of QuidelOrtho Corporation (the “Company”) has appointed Micah Young to serve as the Company’s Chief Financial Officer and principal financial officer, effective as of July 6, 2026
Appointed
Philip McLellan
Chief Operations Officer
QDEL ·
QuidelOrtho Corp
the Company appointed Philip McLellan to serve as the Company’s Chief Operations Officer (“COO”), effective November 15, 2024.
Role change
Joseph M. Busky
Chief Financial Officer
QDEL ·
QuidelOrtho Corp
Joseph M. Busky, the Company’s Chief Financial Officer, assuming additional responsibilities, including oversight of the Company’s Information Technology function, on November 18, 2024
Appointed
Philip McLellan
Chief Operations Officer
QDEL ·
QuidelOrtho Corp
In addition, the Company appointed Philip McLellan to serve as the Company’s Chief Operations Officer, effective as of the Effective Date.
Departed
Robert J. Bujarski
Executive Vice President and Chief Operating Officer
QDEL ·
QuidelOrtho Corp
The Company determined to terminate the employment of Michael S. Iskra, the Company’s Executive Vice President (“EVP”) and Chief Commercial Officer, and Robert J. Bujarski, the Company’s EVP and Chief Operating Officer, each effective November 15, 2024 (the “Effective Date”).
Departed
Michael S. Iskra
Executive Vice President and Chief Commercial Officer
QDEL ·
QuidelOrtho Corp
The Company determined to terminate the employment of Michael S. Iskra, the Company’s Executive Vice President (“EVP”) and Chief Commercial Officer, and Robert J. Bujarski, the Company’s EVP and Chief Operating Officer, each effective November 15, 2024 (the “Effective Date”).
Appointed
Brian J. Blaser
President and Chief Executive Officer
QDEL ·
QuidelOrtho Corp
The Board of Directors (the “Board”) of QuidelOrtho Corporation (the “Company”) has appointed Brian J. Blaser to serve as the Company’s President and Chief Executive Officer, effective as of May 6, 2024 (the “Effective Date”).
Role change
(interim)
Robert J. Bujarski
Interim President
QDEL ·
QuidelOrtho Corp
each of Michael S. Iskra, who served as the Company’s Interim Chief Executive Officer, and Robert J. Bujarski, who served as the Company’s Interim President, stepped down from these interim positions.
Appointed
Brian J. Blaser
director
QDEL ·
QuidelOrtho Corp
In addition, effective as of May 15, 2024, the Board expanded its size from ten to eleven directors and appointed Mr. Blaser to serve as a director until the Company’s 2025 Annual Meeting of Stockholders.
Role change
(interim)
Michael S. Iskra
Interim Chief Executive Officer
QDEL ·
QuidelOrtho Corp
each of Michael S. Iskra, who served as the Company’s Interim Chief Executive Officer, and Robert J. Bujarski, who served as the Company’s Interim President, stepped down from these interim positions.
Appointed
(interim)
Michael S. Iskra
Interim Chief Executive Officer
QDEL ·
QuidelOrtho Corp
the Board also appointed Michael S. Iskra to serve as the Company’s Interim Chief Executive Officer and Robert J. Bujarski to serve as the Company’s Interim President, each effective February 21, 2024.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event earnings